XGN Exagen Inc.

NASDAQ
$6.66

Exagen Inc. (XGN) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $0.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +15.8% since its last earnings release on August 4, 2026.

Exagen Beat Consensus Estimates, Raises Guidance
Tuesday, August 4, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 8:00 AM ET
Earnings Whisper
-
vs ($0.19)
Rev est $18.28M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $6.57

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.

Sector

Healthcare

Industry

Medical Labs & Research